Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction‐associated steatotic liver disease: A prospective, multicentre, observational study
Authors' conclusion
Oral semaglutide treatment for T2DM in patients with MASLD leads to an improvement in liver steatosis and injury, surrogate markers of fibrosis, diabetic status, and lipid profile, and reduces body weight.
Study context
- Population
- Consecutive patients with MASLD and T2D70 completed 48 weeks, analysed
- Participants
- 80 patients
- Exposure
- Oral semaglutide, 48 weeks vs baseline
- Oral semaglutiden = 80
- Outcome
- Efficacy vs baseline
- Follow-up
- 48 weeks
Methodological detailssingle-arm, multicentre
- Single-arm
- Multicentre
Main finding
As reported in the abstract
- Body weight, liver enzymes, lipid profile and glycaemic control significantly improved vs baseline
- all p < 0.01
- Controlled attenuation parameter significantly decreased from baseline
- p < 0.01
- Fibrosis markers (type IV collagen 7S, WFA+-M2BP, fibrosis-4 index, liver stiffness) significantly decreased from baseline
- all p < 0.01
Observational data: associations, not effects.
Further findings
Correlation of changes with change in body weight · 48 weeks
- Change in alanine aminotransferase vs change in body weight
- r = 0.37, p < 0.01
- Change in controlled attenuation parameter vs change in body weight
- r = 0.44, p < 0.01
Safety
Adverse events: Grades 1-2 transient gastrointestinal symptoms (most common)
- Nausea
- 23 patients, 28.8%
- Dyspepsia
- 12, 15.0%
- Appetite loss
- 4, 5.0%
Original publication
Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction‐associated steatotic liver disease: A prospective, multicentre, observational study. Diabetes Obes Metab. Published 2 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →